Theophylline	Warfarin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	11289	D013806	D014859
Theophylline	Warfarin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	11289	D013806	D014859
Theophylline	amoxicillin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	723	D013806	D000658
Theophylline	amoxicillin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	723	D013806	D000658
Theophylline	amoxicillin	11	12	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	723	D013806	D000658
Theophylline	amoxicillin	11	12	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	723	D013806	D000658
Theophylline	warfarin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	11289	D013806	D014859
Theophylline	warfarin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	11289	D013806	D014859
Theophylline	tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	42316	D013806	D016559
Theophylline	tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	42316	D013806	D016559
Theophylline	tacrolimus	11	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		10438	42316	D013806	D016559
Theophylline	tacrolimus	11	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		10438	42316	D013806	D016559
Theophylline	prothrombin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	1441688	D013806	1441688
Theophylline	prothrombin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	1441688	D013806	1441688
Theophylline	clarithromycin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	21212	D013806	21212
Theophylline	clarithromycin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	21212	D013806	21212
Theophylline	clarithromycin	11	12	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	21212	D013806	21212
Theophylline	clarithromycin	11	12	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		10438	21212	D013806	21212
Theophylline	Tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	42316	D013806	D016559
Theophylline	Tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		10438	42316	D013806	D016559
Theophylline	Tacrolimus	11	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		10438	42316	D013806	D016559
Theophylline	Tacrolimus	11	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		10438	42316	D013806	D016559
Theophylline	theophylline	10	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		D013806	D013806
Theophylline	theophylline	10	11	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		D013806	D013806
Theophylline	theophylline	11	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		D013806	D013806
Theophylline	theophylline	11	11	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		D013806	D013806
ketoconazole	Warfarin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	11289	D007654	D014859
ketoconazole	Warfarin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	11289	D007654	D014859
ketoconazole	Warfarin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	11289	D007654	D014859
ketoconazole	Warfarin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	11289	D007654	D014859
ketoconazole	warfarin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	11289	D007654	D014859
ketoconazole	warfarin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	11289	D007654	D014859
ketoconazole	warfarin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	11289	D007654	D014859
ketoconazole	warfarin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	11289	D007654	D014859
ketoconazole	digoxin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	3407	D007654	3407
ketoconazole	digoxin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	3407	D007654	3407
ketoconazole	prothrombin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	1441688	D007654	1441688
ketoconazole	prothrombin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		6135	1441688	D007654	1441688
ketoconazole	prothrombin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	1441688	D007654	1441688
ketoconazole	prothrombin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		6135	1441688	D007654	1441688
ketoconazole	ampicillin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	733	D007654	733
ketoconazole	ampicillin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	733	D007654	733
ketoconazole	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	343047	D007654	343047
ketoconazole	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	343047	D007654	343047
ketoconazole	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	343047	D007654	343047
ketoconazole	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		6135	343047	D007654	343047
Warfarin	warfarin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		D014859	D014859
Warfarin	warfarin	5	6	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		D014859	D014859
Warfarin	warfarin	6	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		D014859	D014859
Warfarin	warfarin	6	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		D014859	D014859
Warfarin	warfarin	6	8	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		D014859	D014859
Warfarin	warfarin	8	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		D014859	D014859
Warfarin	warfarin	8	8	false	none	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		D014859	D014859
Warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
Warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
Warfarin	digoxin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	3407	D014859	3407
Warfarin	digoxin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	3407	D014859	3407
Warfarin	digoxin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	3407	D014859	3407
Warfarin	digoxin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	3407	D014859	3407
Warfarin	prothrombin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	1441688	D014859	1441688
Warfarin	prothrombin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	1441688	D014859	1441688
Warfarin	prothrombin	5	6	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	5	6	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	5	7	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	5	7	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	7	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	7	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	8	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	6	8	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	6	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	6	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	prothrombin	8	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
Warfarin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
Warfarin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
Warfarin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	733	D014859	733
Warfarin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	733	D014859	733
Warfarin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	733	D014859	733
Warfarin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	733	D014859	733
Warfarin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	343047	D014859	343047
Warfarin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	343047	D014859	343047
Warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		11289	10438	D014859	D013806
Warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		11289	10438	D014859	D013806
amoxicillin	clarithromycin	12	12	false	none	[See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	21212	D000658	21212
amoxicillin	clarithromycin	12	12	false	none	[See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	21212	D000658	21212
amoxicillin	theophylline	12	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	10438	D000658	D013806
amoxicillin	theophylline	12	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	10438	D000658	D013806
amoxicillin	theophylline	12	11	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	10438	D000658	D013806
amoxicillin	theophylline	12	11	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		723	10438	D000658	D013806
warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
warfarin	digoxin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	3407	D014859	3407
warfarin	digoxin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	3407	D014859	3407
warfarin	digoxin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	3407	D014859	3407
warfarin	digoxin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	3407	D014859	3407
warfarin	prothrombin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	1441688	D014859	1441688
warfarin	prothrombin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	1441688	D014859	1441688
warfarin	prothrombin	5	6	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	5	6	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	5	7	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
warfarin	prothrombin	5	7	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	6	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	7	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	7	false	none	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	8	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	6	8	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	6	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	6	true	positive	However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	prothrombin	8	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  		11289	1441688	D014859	1441688
warfarin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
warfarin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		11289	42316	D014859	D016559
warfarin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	733	D014859	733
warfarin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	733	D014859	733
warfarin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	733	D014859	733
warfarin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		11289	733	D014859	733
warfarin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	343047	D014859	343047
warfarin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		11289	343047	D014859	343047
warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		11289	10438	D014859	D013806
warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		11289	10438	D014859	D013806
tacrolimus	prothrombin	9	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		42316	1441688	D016559	1441688
tacrolimus	prothrombin	9	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		42316	1441688	D016559	1441688
tacrolimus	prothrombin	9	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		42316	1441688	D016559	1441688
tacrolimus	prothrombin	9	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		42316	1441688	D016559	1441688
tacrolimus	Tacrolimus	9	9	false	none	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		D016559	D016559
tacrolimus	theophylline	9	10	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		42316	10438	D016559	D013806
tacrolimus	theophylline	9	10	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		42316	10438	D016559	D013806
tacrolimus	theophylline	9	11	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		42316	10438	D016559	D013806
tacrolimus	theophylline	9	11	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		42316	10438	D016559	D013806
digoxin	prothrombin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		3407	1441688	3407	1441688
digoxin	prothrombin	4	5	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		3407	1441688	3407	1441688
digoxin	prothrombin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		3407	1441688	3407	1441688
digoxin	prothrombin	4	6	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		3407	1441688	3407	1441688
digoxin	ampicillin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	733	3407	733
digoxin	ampicillin	4	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	733	3407	733
digoxin	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	343047	3407	343047
digoxin	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	343047	3407	343047
digoxin	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	343047	3407	343047
digoxin	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		3407	343047	3407	343047
prothrombin	Tacrolimus	7	9	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		1441688	42316	1441688	D016559
prothrombin	Tacrolimus	7	9	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		1441688	42316	1441688	D016559
prothrombin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		1441688	42316	1441688	D016559
prothrombin	Tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  		1441688	42316	1441688	D016559
prothrombin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		1441688	733	1441688	733
prothrombin	ampicillin	5	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		1441688	733	1441688	733
prothrombin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		1441688	733	1441688	733
prothrombin	ampicillin	6	4	false	none	[See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.  		1441688	733	1441688	733
prothrombin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		1441688	343047	1441688	343047
prothrombin	atazanavir	5	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  [See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).  		1441688	343047	1441688	343047
prothrombin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		1441688	10438	1441688	D013806
prothrombin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		1441688	10438	1441688	D013806
clarithromycin	theophylline	12	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		21212	10438	21212	D013806
clarithromycin	theophylline	12	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		21212	10438	21212	D013806
clarithromycin	theophylline	12	11	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		21212	10438	21212	D013806
clarithromycin	theophylline	12	11	false	none	Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.  		21212	10438	21212	D013806
Tacrolimus	theophylline	9	10	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		42316	10438	D016559	D013806
Tacrolimus	theophylline	9	10	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  		42316	10438	D016559	D013806
Tacrolimus	theophylline	9	11	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		42316	10438	D016559	D013806
Tacrolimus	theophylline	9	11	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  		42316	10438	D016559	D013806
ampicillin	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		733	343047	733	343047
ampicillin	atazanavir	4	2	false	none	Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.  Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		733	343047	733	343047
ampicillin	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		733	343047	733	343047
ampicillin	atazanavir	4	3	false	none	Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.  [See Clinical Pharmacology (12.5)]    It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).  		733	343047	733	343047
